Johnson & Johnson Total Long-Term Assets 2012-2026 | JNJ
Johnson & Johnson total long-term assets from 2012 to 2026. Total long-term assets can be defined as the sum of all assets classified as non-current
- Johnson & Johnson total long-term assets for the quarter ending March 31, 2026 were $143.586B, a 15.6% increase year-over-year.
- Johnson & Johnson total long-term assets for 2025 were $143.586B, a 15.6% increase from 2024.
- Johnson & Johnson total long-term assets for 2024 were $124.211B, a 8.9% increase from 2023.
- Johnson & Johnson total long-term assets for 2023 were $114.063B, a 13.64% decline from 2022.
|
Johnson & Johnson Annual Total Long-Term Assets (Millions of US $) |
|
|---|---|
| 2025 | $143,586 |
| 2024 | $124,211 |
| 2023 | $114,063 |
| 2022 | $132,084 |
| 2021 | $121,039 |
| 2020 | $123,657 |
| 2019 | $112,454 |
| 2018 | $106,921 |
| 2017 | $114,215 |
| 2016 | $76,176 |
| 2015 | $73,201 |
| 2014 | $74,614 |
| 2013 | $76,276 |
| 2012 | $75,231 |
| 2011 | $59,328 |
|
Johnson & Johnson Quarterly Total Long-Term Assets (Millions of US $) |
|
|---|---|
| 2025-12-31 | $143,586 |
| 2025-09-30 | $138,205 |
| 2025-06-30 | $138,891 |
| 2025-03-31 | $122,120 |
| 2024-12-31 | $124,211 |
| 2024-09-30 | $125,038 |
| 2024-06-30 | $123,271 |
| 2024-03-31 | $114,964 |
| 2023-12-31 | $114,063 |
| 2023-09-30 | $112,358 |
| 2023-06-30 | $131,119 |
| 2023-03-31 | $131,581 |
| 2022-12-31 | $132,084 |
| 2022-09-30 | $109,888 |
| 2022-06-30 | $113,877 |
| 2022-03-31 | $117,931 |
| 2021-12-31 | $121,039 |
| 2021-09-30 | $119,339 |
| 2021-06-30 | $122,671 |
| 2021-03-31 | $120,024 |
| 2020-12-31 | $123,657 |
| 2020-09-30 | $113,115 |
| 2020-06-30 | $112,488 |
| 2020-03-31 | $110,791 |
| 2019-12-31 | $112,454 |
| 2019-09-30 | $111,188 |
| 2019-06-30 | $113,318 |
| 2019-03-31 | $108,040 |
| 2018-12-31 | $106,921 |
| 2018-09-30 | $108,509 |
| 2018-06-30 | $109,927 |
| 2018-03-31 | $113,857 |
| 2017-12-31 | $114,215 |
| 2017-09-30 | $113,829 |
| 2017-06-30 | $114,018 |
| 2017-03-31 | $81,571 |
| 2016-12-31 | $76,176 |
| 2016-09-30 | $77,050 |
| 2016-06-30 | $73,523 |
| 2016-03-31 | $73,493 |
| 2015-12-31 | $73,201 |
| 2015-09-30 | $69,772 |
| 2015-06-30 | $71,035 |
| 2015-03-31 | $70,398 |
| 2014-12-31 | $74,614 |
| 2014-09-30 | $72,124 |
| 2014-06-30 | $75,081 |
| 2014-03-31 | $75,961 |
| 2013-12-31 | $76,276 |
| 2013-09-30 | $74,757 |
| 2013-06-30 | $73,052 |
| 2013-03-31 | $74,308 |
| 2012-12-31 | $75,231 |
| 2012-09-30 | $74,160 |
| 2012-06-30 | $74,135 |
| 2012-03-31 | $59,187 |
| 2011-12-31 | $59,328 |
| 2011-09-30 | $58,378 |
| 2011-06-30 | $59,441 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |